SCHEMBL2009658

SCHEMBL2009658

ON=C(c1ccccc1)c1cc(F)cc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.48
GFER P55789 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MGLL Q99685 4/20 0.46
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
XBP1 P17861 1/20 0.41
GAA P10253 1/20 0.39
CYP2C19 P33261 1/20 0.39
CTSL P07711 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2009657 1.00 HPGD (0.48) HPGDGFERALDH1A1MGLLKMT2A
SCHEMBL8635047 0.83 HPGD (0.57) HPGDGFERALDH1A1MGLLKMT2A
SCHEMBL273196 0.82 HPGD (0.64) HPGDGFERALDH1A1MGLLKMT2A
SCHEMBL27961040 0.82 HPGD (0.64) HPGDGFERALDH1A1MGLLKMT2A
Water SCHEMBL9518556 0.79 HPGD (0.61) HPGDGFERALDH1A1MGLLKMT2A
SCHEMBL28341134 0.79 HPGD (0.68) HPGDGFERALDH1A1MGLLKMT2A
SCHEMBL2011191 0.78 CES2 (0.56) KMT2ASMN1; SMN2CTSLCES2CES1
SCHEMBL12789398 0.75 MGLL (0.46) HPGDGFERALDH1A1MGLLKMT2A
Cyclohexane SCHEMBL27981579 0.75 HPGD (0.57) HPGDGFERALDH1A1MGLLKMT2A
SCHEMBL17627139 0.73 MAPT (0.50) ALDH1A1KMT2ASMN1; SMN2MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964645-B2 Glycine transporter gene 1 (GlyT-1); psychosis, schizophrenia, dementia; activation of NMDA receptors via GlyT-1 inhibition; N-(([(4-chloro-phenyl)-phenyl-methyl]-carbamoyl)-methyl)-4-fluorobenzamide for example HOFFMANN-LA ROCHE INC. (US) 2011-06-21 US disclosed
EP-2066620-A1 DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 F. Hoffmann-Roche AG (CH) 2009-06-10 EP disclosed
US-20080076806-A1 Di-aromatic substituted amides as inhibitors for GlyT-1 F. HOFFMANN-LA ROCHE AG (CH) 2008-03-27 US disclosed
WO-2008022938-A1 DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 F. HOFFMANN-LA ROCHE AG (CH) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076806-A1 Di-aromatic substituted amides as inhibitors for GlyT-1 AGXT, SLC1A2, GRIA1 HPGD 3213/4885GFER 2407/4885ALDH1A1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.